Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript
Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript
Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates
Veracyte (VCYT) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.03 per share a year ago.
Veracyte: Revolutionizing Noninvasive Cancer Diagnostics
In this ROBO Global Artificial Intelligence Index spotlight, we focus on Veracyte (VCYT). The index underlies the $137 million ROBO Global Artificial Intelligence ETF (THNQ).
Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now
Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.
Veracyte (VCYT) Up 9.2% Since Last Earnings Report: Can It Continue?
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
Here's Why Veracyte (VCYT) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Veracyte (VCYT) Just Flashed Golden Cross Signal: Do You Buy?
After reaching an important support level, Veracyte, Inc. (VCYT) could be a good stock pick from a technical perspective. VCYT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Veracyte, Inc. (VCYT) Hit a 52 Week High, Can the Run Continue?
Veracyte (VCYT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Veracyte (VCYT) Q2 Earnings Beat Estimates, '24 Sales View Up
Veracyte's (VCYT) second-quarter 2024 performance reflects the strength of its testing business.
Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View
On Tuesday, Veracyte, Inc VCYT reported second-quarter sales of $114.43 million, up 27% year over year, beating the consensus of $100.3 million.
Veracyte, Inc. (VCYT) Q2 2024 Earnings Call Transcript
Veracyte, Inc. (NASDAQ:VCYT ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Shayla Gorman – Senior Director, Investor Relations Marc Stapley – Chief Executive Officer Rebecca Chambers – Chief Financial Officer Conference Call Participants Mason Carrico – Stephens, Inc. Yuko Oku – Morgan Stanley Maggie Boeye – William Blair Joseph Conway – Needham & Company Prashant Kota – Goldman Sachs Thomas DeBourcy – Nephron Research Operator Good day and thank you for standing by. Welcome to the Veracyte Second Quarter 2024 Financial Results Call.
